Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced, that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for KYNAMRO™ (mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).....
Med-Chemist : "Quintessential Medicinal Chemistry"
No comments:
Post a Comment